Description
Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist designed to help improve blood sugar control in adults with type 2 diabetes. It is administered as a once-weekly subcutaneous injection and has also been studied for weight management benefits.
•Form: Prefilled injection pen
•Strengths: 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, 15 mg/0.5 mL
•Use: Weekly subcutaneous injection
•Note: Prescription required.
Reviews
There are no reviews yet.